Biopharmaceuticals Contract Manufacturing Market To Reach $100.8 Billion By 2033

Biopharmaceuticals Contract Manufacturing Market Growth & Trends

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 100.8 billion by 2033, registering a CAGR of 10.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 

 Request a free sample copy or view the report summary: Biopharmaceuticals Contract Manufacturing Market Report

Biopharmaceuticals Contract Manufacturing Market Report Highlights

• By source, the mammalian segment led the market with the largest revenue share of 58.9% in 2025. The non-mammalian segment is projected to register the fastest CAGR during the forecast period.

• By service, the process development segment led the market with the largest revenue share of 34.7% in 2025. The analytical and QC studies segment is expected to register the fastest CAGR during the forecast period.

• By drug type, the biologics segment led the market with the largest revenue share of 78.1% in 2025. The biosimilars segment is projected to witness the fastest CAGR during the forecast period.

• By type, the drug substance segment led the market with the largest revenue share of 57.6% in 2025. The finished drug product segment is anticipated to register the fastest CAGR during the forecast period.

• By scale of operation, the commercial segment led the market with the largest revenue share of 75.1% in 2025.  The clinical segment is projected to register the fastest CAGR during the forecast period.

• By therapeutic area, the oncology segment led the market with the largest revenue share of 38.3% in 2025. The autoimmune diseases segment is expected to register a significant CAGR during the forecast period.

Biopharmaceuticals Contract Manufacturing Market Segmentation

Grand View Research has segmented global biopharmaceuticals contract manufacturing market report based on source, service, drug type, type, scale of operation, therapeutic area, and region:

Biopharmaceuticals Contract Manufacturing Source Outlook (Revenue, USD Billion, 2021 - 2033)

• Mammalian

• Non-mammalian

Biopharmaceuticals Contract Manufacturing Service Outlook (Revenue, USD Billion, 2021 - 2033)

• Process Development

  • Downstream

  • Upstream

• Fill & Finish Operations

• Analytical & QC studies

• Packaging & Labelling

• Others

Biopharmaceuticals Contract Manufacturing Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Biologics

  • Monoclonal antibodies (mAbs)

  • Recombinant Proteins

  • Vaccines

  • Antisense, RNAi, & Molecular Therapy

  • Others

• Biosimilars

Biopharmaceuticals Contract Manufacturing Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Drug Substance

• Finished Drug Product

Biopharmaceuticals Contract Manufacturing Scale of Operation Outlook (Revenue, USD Billion, 2021 - 2033)

• Clinical

• Commercial

Biopharmaceuticals Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)

• Oncology

• Autoimmune Diseases

• Infectious Diseases

• Cardiovascular Diseases

• Metabolic Diseases

• Neurology

• Others

Biopharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Billion, 2021 - 2033) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players of Biopharmaceuticals Contract Manufacturing Market

• Boehringer Ingelheim GmbH

• Lonza

• Inno Biologics Sdn Bhd

• Rentschler Biotechnologie GmbH

• JRS PHARMA

• AGC Biologics

• ProBioGen

• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

• Toyobo Co. Ltd.

• Samsung Biologics

• Thermo Fisher Scientific, Inc.

• Binex Co., Ltd.

• WuXi Biologics

• AbbVie, Inc.

• ADMA Biologics, Inc.

• Catalent, Inc

• Cambrex Corporation

• Pfizer Inc.

• Siegfried Holding AG